WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
China will not peak as forecasted by the 'China peak theory': FM spokespersonSunny Sanya will see a luxury mega complex builtFloriade Expo 2022 opens in Almere, the NetherlandsXi Meets Sogavare, Urging Enhanced ChinaXi Meets Russian Federation Council SpeakerHighlights of Beijing 2022 Paralymic Torch Relay and Flame Lighting Ceremony85 ancient tombs unearthed in Upper EgyptChina's cargo, container throughput rises in first two monthsChina welcomes global enterprises at consumer expo in HaikouXinhua Headlines: A solidly modernizing China to chart blueprint for year 2022